Clinical pharmacokinetics of vindesine infusion
- PMID: 2410121
Clinical pharmacokinetics of vindesine infusion
Abstract
Fifteen patients were given vindesine (VDS) either by iv bolus injections at doses ranging from 0.7 to 1.2 mg/m2 or by 5-day infusions (total dose: 5 mg/m2), in combination with cisplatin (20 mg/m2/day) and bleomycin (6 mg/m2/day) for 5 days. For bolus injections, the total dose of VDS in one treatment was completed to 5 mg/m2 by infusion on Days 4 and 5. Drug concentrations in plasma and urine were measured by radioimmunoassay. Plasma concentration decay curves after bolus injection presented the expected triphasic shape, whereas for infusions, plasma concentrations increased and reached steady-state after about 30 hours and declined in a biphasic way after infusion discontinuation. Steady-state concentrations ranged from 4 to 15 micrograms/L and showed important variations among patients. Clearances estimated from the area under the concentration-time curves were significantly smaller for infusions than for bolus injections. This observation was interpreted as an indication of VDS pharmacokinetic nonlinearity. Terminal half-lives and renal clearances were not significantly different for the two types of administration. Toxicity of the treatment was generally limited, except for one major renal failure; two patients showed objective tumor regression after therapy.
Similar articles
-
Pharmacokinetics of vindesine bolus and infusion.Cancer Chemother Pharmacol. 1984;13(2):114-9. doi: 10.1007/BF00257126. Cancer Chemother Pharmacol. 1984. PMID: 6467494
-
Pharmacokinetics of vindesine given as an intravenous bolus and 24-hour infusion in humans.Cancer Res. 1985 Jan;45(1):464-9. Cancer Res. 1985. PMID: 3965152
-
Initial clinical study with vindesine: tolerance to weekly iv bolus and 24-hour infusion.Cancer Treat Rep. 1980 Jan;64(1):25-30. Cancer Treat Rep. 1980. PMID: 6929728
-
[Five-day continuous infusion of vindesine in the treatment of non-small cell lung cancer--clinical pharmacokinetics of vindesine].Gan To Kagaku Ryoho. 1991 Sep;18(12):2129-32. Gan To Kagaku Ryoho. 1991. PMID: 1653559 Japanese.
-
Continuous infusion or bolus injection in cancer chemotherapy.Ann Intern Med. 1983 Dec;99(6):823-33. doi: 10.7326/0003-4819-99-6-823. Ann Intern Med. 1983. PMID: 6197002 Review.
Cited by
-
Phase I study of 21 days continuous infusion with vindesine.Br J Cancer. 1989 Mar;59(3):471-2. doi: 10.1038/bjc.1989.97. Br J Cancer. 1989. PMID: 2930717 Free PMC article. No abstract available.
-
Preclinical and clinical pharmacology of vinca alkaloids.Drugs. 1992;44 Suppl 4:1-16; discussion 66-9. doi: 10.2165/00003495-199200444-00002. Drugs. 1992. PMID: 1283846 Review.
-
In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide).Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):49-55. doi: 10.1007/BF03190127. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2384117
-
In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. II. Vinblastine and vincristine.Eur J Drug Metab Pharmacokinet. 1990 Oct-Dec;15(4):323-32. doi: 10.1007/BF03190222. Eur J Drug Metab Pharmacokinet. 1990. PMID: 2088769
-
P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier.Pharm Res. 2001 May;18(5):587-92. doi: 10.1023/a:1011016923346. Pharm Res. 2001. PMID: 11465412